Newsletter subscription & archive

Better Science, Better Health on the Agenda


At the end of October 2015, the World’s Thought Leaders in New Healthcare Models from both sides of the Atlantic gathered at the US Congress in Washington, DC to discuss new health care models. The basis for the theme of this conference was the current wave of unprecedented medical innovation, where we live with regulatory, reimbursement and healthcare systems that fail to deliver the benefits to patients.

A number of research projects, pilots and other initiatives investigate how to improve translation from bench to bedside. This is necessary and there is an increasing need to find ways of collaborating internationally to ensure application of research outputs to reduce costs and timelines in drug development. Precision medicine should soon be a reality, leading to better outcomes. Better science should indeed result in better health.

The conference comprised two days of high-level discussion and debate by experts across the healthcare value chain and from both sides of the Atlantic, DIA (the Drug Information Association), IMI (the Innovative Medicines Initiative), and EFPIA (European Federation of Pharmaceutical Industries and Associations) were present as well as other key global players,

During the two days, speakers and delegates addressed themes of priority in a list of action points to drive new healthcare models forward and advance the implementation of precision medicine and patient centred healthcare models. The action points included:

  • Improving information and communication technology infrastructures incl. data analyses of data
  • Privacy and security of information in patient health records and health databases
  • Adaptive approaches to clinical trials and regulatory pathways aiming to remove boundaries between research and clinical practice
  • Intellectual property rights in a data sharing world
  • New business models bringing e.g. diagnostics tests and health care systems costs together
  • Involvement and empowerment of patients and the utilization of real life data
  • Regulatory science and new ways to collaborate in a multi-disciplinary environment since the existing tools of regulatory science are not sufficient for the personalized medicine future. There is a need for new tools, professionalization and enhancement of regulatory science as a discipline in its own right. Expansion of boundaries to take in the social sciences, providing channels for patients to have a full say in what outcomes matter to them
  • Training and education of scientists in discovery labs to regulators and healthcare professionals


Biopeople is already deeply involved in projects reflecting several of these action points, since activities reflecting the development of precision medicine is one of our main priorities in the coming years.

Per Spindler, Director, Biopeople

What are you looking for?
By using this website, you agree to the use of cookies to give you the best user experience.
Find additional information at Cookies